Skip to content

Analgesic Contribution of the Suprazygomatic Maxillary Nerve Block for Cleft Palate Surgery in Children

Analgesic Contribution of the Suprazygomatic Maxillary Nerve Block for Cleft Palate Surgery in Children

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04023825
Acronym
Suprazyg
Enrollment
0
Registered
2019-07-18
Start date
2019-07-01
Completion date
2022-07-01
Last updated
2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cleft Palate, Surgery

Keywords

cleft palate, surgery, maxillary nerve block, local anesthetic, loco regional anesthesia, face nerve block

Brief summary

This is a monocentric prospective randomized simple-blind designed study evaluating the superiority of the suprazygomatic maxillary nerve block in analgesia after cleft palate surgery compared with a control group. Every two hours, nurses systematically reassess the patient's pain and adjust the analgesic medications. Analgesic requirement, incidence of respiratory complications, re-feeding time and the duration of hospitalization are evaluated.

Detailed description

Cleft palate is the most common congenital malformation and requires early surgery given the complications it generates. The surgical site involving the upper airways and the use of morphine are providers of respiratory complications. The suprazygomatic maxillary nerve block could considerably reduce the use of morphine in the postoperative period and thus the respiratory complications in addition to an optimal comfort for the patient. The primary endpoint was to evaluate morphine consumption during the first postoperative 48 hours after cleft palate surgery.

Interventions

in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Months to 12 Years
Healthy volunteers
No

Inclusion criteria

* children between 5 months and 12 years old * weight \>5kg * children undergoing cleft palate repair surgery with or without upper lip surgery

Exclusion criteria

* inappropriate age * weight \<5kg * abnormal blood coagulation * local anesthetic contraindication (including levobupivacaine, as well as any other associated treatment administered in this clinical study, including opioids, general anesthetics such as ketamine or propofol, paracetamol or corticosteroids) * local infection

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline of morphine consumptionup to 48 hours after cleft palate surgeryThe main objective of this study is to compare the consumption of morphine during the first 48 hours after cleft palate surgery in a group of patients treated by realization of a suprazygomatic maxillary nerve block, compared to a control group.

Secondary

MeasureTime frameDescription
Change from baseline of consumption of perioperative morphineup to one week after cleft palate surgeryevaluation of the consumption of perioperative morphine
Measure of the number of episodes of respiratory distressup to one week after cleft palate surgeryMeasure of the number of episodes of respiratory distress
Measure of the period of re-feedingup to one week after cleft palate surgeryMeasure of the period of re-feeding
Measure of the duration of hospitalizationup to one week after cleft palate surgeryMeasure of the duration of hospitalization

Contacts

PRINCIPAL_INVESTIGATORMatthieu Miclo, MD

CHU Amiens

PRINCIPAL_INVESTIGATOREmmanuel Lorne, Pr

CHU Amiens

PRINCIPAL_INVESTIGATORJérémie Garnier, MD

CHU Amiens

PRINCIPAL_INVESTIGATORMarie Trujillo-Garcia, MD

CHU Amiens

PRINCIPAL_INVESTIGATORDimitri Santarelli, MD

CHU Amiens

PRINCIPAL_INVESTIGATORCica Carole Gbaguidi, MD

CHU Amiens

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026